Answers are grounded in this paper and cite their sources.
Demonstrates resistance to CDK4/6 inhibitors in breast cancer patients with BRCA2 mutations, suggesting challenges in treatment effectiveness.
While CDK4/6 inhibitors have revolutionized the management of patients with breast cancer, the clinical benefits of these agents remain limited by resistance mechanisms. Recent findings demonstrate that germline BRCA2 mutations foster resistance to CDK4/6 inhibitors via RB1 loss-of-function alterations that (in some cases) are acquired through persistent homologous recombination defects.
No takes yet. Share an insight, caveat, or question.
Bolini et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: